

*New Directions for Type 2 Diabetes Mellitus Management*

Proceedings of this supplement to *The American Journal of Managed Care* are based on presentations and discussions that took place during a roundtable meeting titled "New Directions for Type 2 Diabetes Mellitus Management," held in September 2001. This supplement has been peer reviewed by an expert in the field.

---

*Chair*

**Lawrence Blonde, MD**

Section on Endocrinology, Diabetes,  
and Metabolic Diseases  
Department of Internal Medicine  
Director, Ochsner Diabetes Clinical Research Unit  
Ochsner Clinic and Alton Ochsner Medical Foundation  
New Orleans, Louisiana

*Faculty*

**Azar Afaq, MD**

Section on Endocrinology,  
Diabetes, and Metabolic  
Diseases  
Department of Internal Medicine  
Ochsner Clinic Foundation  
New Orleans, Louisiana

**Francis M. Collins, MD**

Queen City Physicians  
Cincinnati, Ohio

**Terrance Killilea, PharmD**

Assistant Vice President  
Pharmacy Services  
Regency Blue Shield of Idaho  
Boise, Idaho

**David J. Kudzma, MD**

Medical Director  
United Healthcare of Florida  
Sunrise, Florida

**Ram Pathak, MD**

Section on Endocrinology,  
Diabetes, and Metabolic  
Diseases  
Department of Internal Medicine  
Ochsner Clinic Foundation  
New Orleans, Louisiana

**Gregory E. Tennyson, MD**

Endocrinology Consultant  
Bronson Healthcare Group  
Kalamazoo, Michigan

---

## DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants declare the following affiliations with corporate organizations:

■ **Lawrence Blonde, MD**

*Consultant To And/Or Received*

*Honoraria From:*

Amilyn  
Aventis  
Bayer  
Becton Dickinson  
Bristol-Myers Squibb  
Eli Lilly  
GlaxoSmithKline  
MedicalLogic  
Medscape  
Merck  
Novo-Nordisk  
Novartis  
Parke-Davis  
Pfizer  
SmithKline Beecham

*Investigator Or Subinvestigator*

*In Clinical Trials Sponsored By:*

Amilyn  
Aventis  
Bayer  
Becton Dickinson  
Bristol-Myers Squibb  
Eli Lilly  
GlaxoSmithKline  
MedicalLogic  
Medscape  
Merck  
Novo-Nordisk  
Novartis  
Parke-Davis  
Pfizer  
Proctor & Gamble  
SmithKline Beecham

■ **Francis M. Collins, MD**

*Advisor To/Speakers' Bureau For:*

Eli Lilly  
Pfizer  
GlaxoSmithKline  
Novartis  
Aventis

■ **Gregory E. Tennyson, MD**

*Speakers' Bureau/Consultant To:*

GlaxoSmithKline

These participants declare no financial arrangement or affiliation with any corporate organizations:

■ **Azar Afaq, MD**

■ **Terrance Killilea, PharmD**

■ **David J. Kudzma, MD**

■ **Ram Pathak, MD**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

---

*New Directions for Type 2 Diabetes Mellitus Management*

This program is supported by an educational grant from **GlaxoSmithKline**.



The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.